Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study by Rousselot, Philippe et al.
Pioglitazone together with
imatinib in chronic myeloid
leukemia: A proof of concept study
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Rousselot, P., S. Prost, J. Guilhot, L. Roy, G. Etienne, L. Legros, A.
Charbonnier, et al. 2016. “Pioglitazone together with imatinib in
chronic myeloid leukemia: A proof of concept study.” Cancer 123
(10): 1791-1799. doi:10.1002/cncr.30490. http://dx.doi.org/10.1002/
cncr.30490.
Published Version doi:10.1002/cncr.30490
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490745
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Pioglitazone Together With Imatinib in Chronic Myeloid
Leukemia: A Proof of Concept Study
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Laurence Legros, MD, PhD6; Aude Charbonnier, MD7; Valerie Coiteux, MD8; Pascale Cony-Makhoul, MD9;
Francoise Huguet, MD10; Emilie Cayssials, MD3; Jean-Michel Cayuela, PharmD, PhD11; Francis Relouzat, PhD2;
Marc Delord, PhD12; Heriberto Bruzzoni-Giovanelli, MD, PhD13,14; Laure Morisset15; Franc¸ois-Xavier Mahon, MD, PhD16;
Franc¸ois Guilhot, MD3; and Philippe Leboulch, MD2,17,18; on behalf of the French CML Group
BACKGROUND: We recently reported that peroxisome proliferator-activated receptor g agonists target chronic myeloid leukemia
(CML) quiescent stem cells in vitro by decreasing transcription of STAT5. Here in the ACTIM phase 2 clinical trial, we asked whether
pioglitazone add-on therapy to imatinib would impact CML residual disease, as assessed by BCR-ABL1 transcript quantification.
METHODS: CML patients were eligible if treated with imatinib for at least 2 years at a stable daily dose, having yielded major molecu-
lar response (MMR) but not having achieved molecular response 4.5 (MR4.5) defined by BCR-ABL1/ABL1IS RNA levels0.0032%. After
inclusion, patients started pioglitazone at a dosage of 30 to 45mg/day in addition to imatinib. The primary objective was to evaluate
the cumulative incidence of patients having progressed from MMR to MR4.5 over 12 months. RESULTS: Twenty-four patients were in-
cluded (age range, 24-79 years). No pharmacological interaction was observed between the drugs. The main adverse events were
weight gain in 12 patients and a mean decrease of 0.4g/dL in hemoglobin concentration. The cumulative incidence of MR4.5 was 56%
(95% confidence interval, 37%-76%) by 12 months, despite a wide range of therapy duration (1.9-15.5 months), and 88% of 17 evaluable
patients who were still on imatinib reached MR4.5 by 48 months. The cumulative incidence of MMR to MR4.5 spontaneous conversions
over 12 months was estimated to be 23% with imatinib alone in a parallel cohort of patients. CONCLUSION: Pioglitazone in combina-
tion with imatinib was well tolerated and yielded a favorable 56% rate. These results provide a proof of concept needing confirmation
within a randomized clinical trial (EudraCT 2009-011675-79). Cancer 2017;123:1791-9. VC 2016 The Authors. Cancer published by Wiley
Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attri-
bution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is prop-
erly cited and is not used for commercial purposes.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the t(9;22)(q34;q11.2) translocation and
its cytogenetic hallmark, the Philadelphia chromosome (der22). This translocation results in a BCR-ABL1 fusion gene that
codes for a BCR-ABL1 oncoprotein (p210BCR-ABL) with enhanced tyrosine kinase activity. BCR-ABL1 is present in all cells
of the leukemic clone, including leukemic hematopoietic stem cells.1 The ability of BCR-ABL1 to induce a similar disease in
mice resulted in the design of tyrosine kinase inhibitors (TKIs), a new class of anticancer agents, the first of which was
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imatinib (Gleevec, Novartis Pharmaceuticals).2 Efficacy
and tolerability were determined in the phase 3 IRIS trial,3
and 15 years later, the long-term survival rate of CML
patients in chronic phase receiving continuous TKI therapy
closely matches that of the non-CML population.4
Residual disease in CML patients is detected by
quantifying the BCR-ABL1 transcripts (BCR-ABL1/
ABL1) by way of real-time quantitative polymerase chain
reaction (RTQ-PCR).5 Definitions of molecular
responses have evolved over the years. Molecular response
4.5 (MR4.5) corresponds to a 4.5-log reduction from a
standardized baseline (BCR-ABL1/ABL1 0.0032% on
the International Scale) and represents a reproducible as-
sessment of deep molecular response. Residual CML dis-
ease remains detectable above the level of MR4.5 in 40%
to 90% of patients in spite of sustained imatinib therapy.6
Patients achieving stable and durable MR4.5 may partici-
pate in treatment free remission studies. In that patient
population, discontinuation of imatinib resulted in mo-
lecular relapse in 40% to 60% of patients, depending on
the chosen definition of molecular relapse.7-9 Although
their clinical significance is unclear, BCR-ABL1 positive
progenitor cells are found in virtually all patients treated
with imatinib, dasatinib, or nilotinib, emphasizing the
need to target and control the residual CML stem cell
pool in an effort to eradicate the disease.10-14
We reported recently that peroxisome proliferator-
activated receptor (PPAR)-c agonists, including the drug
pioglitazone, are capable of eroding the CML leukemia
stem cell pool in biological assays and 3 anecdotal clinical
cases treated for associated type 2 diabetes or off-label.15
PPAR-c agonists are currently used as antidiabetic drugs
that are not hypoglycemogenic in healthy individuals.
Whereas CML stem cells in quiescence resist TKI toxicity,
pioglitazone is capable of pulling them out quiescence,
thereby sensitizing them to imatinib toxicity.15 To evaluate
the potential therapeutic value of PPAR-c agonists in
CML, we initiated a proof of concept phase 2 study termed
ACTIM (actos1 imatinib) to score the cumulative inci-
dence of progression from major molecular response
(MMR) to MR4.5 over 12 months in CML patients who
were given pioglitazone in addition to imatinib.
METHODS
Patients and Synopsis of Study Protocol
The ACTIM study is a proof of concept prospective phase
2 trial conducted in centers from the French CMLGroup.
Adult CML patients were eligible if they were 1) in chron-
ic phase, 2) treated with imatinib for more than 2 years
with no dose modification within the last 3 months, and
3) in MMR, defined by BCR-ABL1/ABL1IS 0.1% with-
out MR4.5 at study initiation (see detailed methods in the
Supporting Information).
The planned therapy consisted in the continuation of
imatinib at the same daily dose per patient (400mg to
800mg) with the addition of pioglitazone 30mg/d during
the first 2 months and 45mg/d thereafter. The study was
amended in June 2011 in order to limit the duration of
pioglitazone therapy to 12 months and to stop recruitment
after completion of the first step of the study. This amend-
ment was requested by the French health regulatory agency
(ANSM) after their decision to withdraw pioglitazone
from market on the basis of results of epidemiologic stud-
ies that suggested an increased risk of bladder carcinoma in
patients with diabetes who have had long-term exposure to
pioglitazone, although ANSM had granted us a special au-
thorization to continue pioglitazone for ACTIM.16,17
Response Definition and Primary Endpoint
The primary endpoint, referred to hereafter as the
“molecular response,” was the percentage of patients
achieving MR4.5 by 12 months at 1 or more scheduled
determinations, as defined by a BCR-ABL1/ABL1 ratio
of 0.0032% on the International Scale according to the
European Leukemia Net recommendations for minimal
residual disease quantification.18 Polymerase chain reac-
tion analysis was centralized at study entry and then mo-
lecular assessments were performed in hospital
laboratories of the French Quality Control Network for
BCR-ABL1 Quantification (Groupe de Biologie Molecu-
laire des Hemopathies Malignes).
Biomarker Analyses and Secondary Endpoints
Secondary endpoints included 1) safety and efficacy anal-
yses at different time points, 2) measurement of STAT5
RNA levels, and 3) colony-forming cell (CFC) assays be-
fore and during the study (months 6 and 12) (see detailed
methods in the Supporting Information). Measurement
of BCR-ABL1/ABL1IS RNA levels was performed every 2
months during the 12 months of study. One patient was
lost from follow-up after the study period, and long-term
follow-up data were collected.
Statistics
It was necessary to include 24 assessable patients in the
first step of the study reported here (see detailed methods
in Supporting Information). Because no competing
events were recorded, the cumulative incidence of molec-
ular response rate at 12 months, the primary endpoint,
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was estimated using the Kaplan–Meier method and con-
ducted on an intent-to-treat principle. Additional sensi-
tivity analyses at different time points were then added.
Secondary endpoints regarding patient characteris-
tics and biomarker evolution over time were investigated
with the use of paired-sample tests. Cumulative inciden-
ces of molecular response rate within subgroups were es-
timated by the Kaplan–Meier method and compared
using the Wilcoxon test. Confidence intervals were esti-
mated at the 95% confidence level, and 2-sided P val-
ues< .05 were considered to indicate statistical
significance. Statistical analyses were performed using
SAS version 9.3 (SAS Institute, Cary, NJ) and R (The R
Foundation for Statistical Computing).
RESULTS
Patient Characteristics
From December 2009 through November 2010, 27
CML patients, all in chronic phase, were recruited and
screened. Three patients were in screen failure, 1 patient
was already in MR4.5 at the screening visit, 1 patient was
not in MMR, and 1 patient withdrew consent. None of
these patients received pioglitazone. Twenty-four patients
were eligible and evaluable (Fig. 1) and were classified on
the basis of age, sex ratio, Sokal risk score,19 time since di-
agnosis, and quantitative criteria of imatinib therapy (Ta-
ble 1). Fourteen patients were in MMR without achieving
MR4 (58%) and 10 patients were in MR4 without achiev-
ing MR4.5 (42%). Of note, 12 patients were treated with
imatinib more than 400mg/d at inclusion reflecting pre-
vious dose adaptations. All these patients were in stable re-
sponse before inclusion and did not achieved MR4.5
previously.
Pioglitazone Administration
All eligible patients started pioglitazone at a dosage of
30mg/d and increased the dose to 45mg/d after 2 months
of therapy. A total of 9 patients (37.5%) discontinued
pioglitazone before month 12. Eight of them did so be-
cause their physician–investigator decided to stop piogli-
tazone administration after France’s ANSM issued a
Figure 1. Flow chart outlining the ACTIM study.
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report of a possible increased risk of bladder carcinoma.
Despite this early termination of pioglitazone, 5 patients
achieved MR4.5 during the 12-month follow-up period.
The first 2 patients included in the study received pioglita-
zone for longer than 12 months (14.5 and 15.5 months)
before the limitation of pioglitazone treatment duration
to 12 months. As a result, the median duration of pioglita-
zone therapy was 11.2 months (range, 1.9-15.5 months).
The median cumulative dose of pioglitazone for each pa-
tient was 13,957mg (range, 1710-19,815mg), which cor-
responds to a median daily dose of 40mg; dosage
intensity during the 12-month follow-up period for all
patients was 32mg/d (Table 1). No patient had to reduce
the dosage of imatinib during the study. Levels of imati-
nib were not statistically different at inclusion (median
dosage, 890 ng/mL [range, 437-2436 ng/mL]) and after 1
month of combined therapy (median dosage, 846 ng/mL
[range, 395-2665 ng/mL]; P5 .46).
Safety
Exploratory analyses were conducted on safety data. A
modest decrease in the median value of hemoglobin con-
centration was observed between inclusion and month 12
(12 g/dL [range, 9.3-14.7 g/dL] vs 11.6 g/dL [range, 9.3-
15.1 g/dL]; P5 .03 [paired t test]). The median neutro-
phil and platelet counts were not different at inclusion
compared with month 12 (neutrophils, 2.6 giga/L vs 2.7
giga/L; P5 .11 [paired t test]; platelets, 209 giga/L vs 218
giga/L; P5 .72 [paired t test]).
All patients were monitored with bladder ultraso-
nography every 6 months during the study period and ev-
ery 12 months thereafter. No case of bladder carcinoma
was reported. Only 1 grade 3 adverse event was recorded
(hypokalemia). As expected, no episode of hypoglycemia
was recorded. HbA1C and total cholesterol levels were
not modified during the 12-month follow-up (Support-
ing Table 1). Overall, weight was stable over time (medi-
an, 81.5 kg at inclusion vs 82 kg at month 12, P5 .27
[paired t test]), although 12 patients experienced a weight
gain (grade 1). One patient stopped because of G2 edema.
Compared with baseline adverse events before pioglita-
zone initiation, no significant increase in other adverse
events was observed (Supporting Table 2).
Efficacy
Molecular efficacy
Thirteen patients (54%) achieved MR4.5 during the 12-
month follow-up period (Table 2). Out of the13 patients
in MMR and not in MR4, 4 (30.7%) achieved MR4.5 by
12 months. The estimated cumulative incidence of molec-
ular response was 56% (95% confidence interval [CI], 37-
76) by 12 months (3 nonresponding patients were evaluat-
ed at month 11) (Fig. 2A). Early discontinuation of piogli-
tazone was not considered a competitive event for
molecular response achievement. At 12 months, 7 patients
(29.1%) remained in MR4.5, whereas 6 patients presented
fluctuations of the BCR-ABL1 transcript around the level
of MR4.5 before they stabilized (Table 2). Twenty-three
out of 24 eligible patients were followed in the long term
(median follow-up period, 5.1 years [range, 4.5-5.8 years]).
One patient aged 66 years died frommultiple myeloma di-
agnosed after CML 4.5 years after inclusion. At 48 months
since inclusion, 14 patients (58.3%) continued to be in
MR4.5. Focusing on the 17 patients who were evaluable
during the follow-up period and who were never switched
to another TKI, most of the 12-month nonresponders
were able to reach molecular response after the study, so
that 15 of those 17 evaluable patients (88.2%) reached
MR4.5 by 48months after pioglitazone priming.
Estimation of MMR to MR4.5 conversion rates with
imatinib alone
Although without the probative value of prospective stud-
ies, we estimated the spontaneous rate of MMR to MR4.5
conversions in a parallel cohort of CML patients not in-
cluded in the ACTIM trial with similar characteristics
(Supporting Table 3). The cumulative incidence of
MR4.5 conversions over a 12-month period in this patient
population (n5 24), as defined in ACTIM for the
TABLE 1. Patient Characteristics for ACTIM Phase 2
Trial
Characteristic Value
No. of patients 24
Age, y, median (range) 61 (24-79)
CML phase, % in chronic 100
Sex ratio, men/women 17/7
Sokal score, low/intermediate/high/unknown 13/4/5/2
Time since diagnosis, mo, median (range) 75 (31-174)
Duration of imatinib treatment, mo,
median (range)
73 (31-129)
Imatinib daily dose at inclusion, mg/d,
median (range)
500 (400-800)
Imatinib [C] min at inclusion, ng/mL,
median (range)
890 (437-2436)
Molecular response at inclusion, n (%)
MMR 14 (58)
MR4 10 (42)
Pioglitazone treatment duration, mo,
median (range)
11.2 (1.9-15.5)
Median pioglitazone daily dose, mg 40
Pioglitazone dosage intensity over
12 months, mg/d
32
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molecular response, was estimated to be 23% (95% CI, 3-
55) (Fig. 2B).
Associated biological markers
We evaluated biomarkers reflecting pioglitazone exposure.
STAT5 RNA expression levels were assessed in
CD341 cells from bone marrow at inclusion in 18 evalu-
able patients and during follow-up in 20 patients, includ-
ing 15 patients with paired analysis at inclusion and at 6
months. STAT5 RNA levels were expressed relative to
GAPDH, and median values were 0.129 (range, 0.098-
0.266) before and 0.066 (range, 0.016-0.129) 6 months af-
ter pioglitazone initiation, showing a reduction in STAT5
RNA levels after pioglitazone treatment (P< .0001 [paired
t test]) (Fig. 3A). CFC assays with patients’ bone marrow
CD341 cells were performed at inclusion, at 6 months af-
ter pioglitazone initiation, and at 12 months after pioglita-
zone initiation in 20, 19, and 5 patients, respectively. The
median numbers of colonies were 429 (range, 269-619) at
inclusion, 279 (range, 120-566) at 6 months, and 279
(range, 187-300) at 12 months. Paired comparisons at in-
clusion and at 6 months showed a reduction in clonogenic-
ity (P5 .0003) (Fig. 3B). We observed a trend for
favorable kinetics ofMR4.5 conversions in patients with the
higher percentage of CFC reduction (P5 .044 by the Wil-
coxon test) (Supporting Fig. 1). No significant correlation
was evidenced between STAT5 RNA expression in normal
CD341 cells and molecular response.
Figure 2. Cumulative incidences of MR4.5 progression by 12 months. (A) Thirteen patients (56% [95% CI, 37%-76% (dotted lines)])
included in the ACTIM study achieved MR4.5 during the 12-month study period. Median time to MR4.5 was 10.6 months [95% CI, 6
months-not determined]. (B) Cumulative incidence of MMR to MR4.5 progression by 12 months in a parallel group of CML patients
having never received pioglitazone. Patient characteristics were comparable to those in the ACTIM study (Supporting Table 3).
Five patients achieved MR4.5 during the 12-month follow-up period. The cumulative incidence of MR4.5 was 23% (95% CI, 3%-55%
[dotted lines]) by 12 months.
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DISCUSSION
We report here the ACTIM phase 2 trial on the use of the
PPAR-c agonist pioglitazone in addition to imatinib in
CML patients not achieving MR4.5 with imatinib alone.
Pioglitazone was administered at 30 to 45mg/d, a dose
commonly used in type 2 diabetes patients. Overall,
patients were exposed to a lower dosage intensity of
32mg/d. Therapy with pioglitazone was not prolonged
over 12 months, as requested by the regulatory agency of
France, and some patients interrupted the treatment pre-
maturely. Despite this limitation, progression from
MMR to MR4.5 was observed in 13 patients (54%),
resulting in a cumulative incidence of molecular response
of 56% by 12 months. During follow-up after pioglita-
zone priming, 88% of 17 evaluable imatinib patients
reached MR4.5 by 48 months, suggesting that the effects
of pioglitazone may be delayed.
Because pioglitazone and other PPAR-c agonists are
already approved for the treatment of type 2 diabetes, we
anticipate that the biological results we reported recently
may influence the management of CML patients by clini-
cians outside the setting of a clinical trial.15 This is why
we launched the ACTIM phase 2 trial as a proof-of-
principle study, although in the absence of a control group
of patients, the benefit of pioglitazone in combination
with imatinib observed here needs to be confirmed by
subsequent randomized studies. However, 2 lines of evi-
dence tend to support the overall conclusion, pending
randomized trials. First, patients on ACTIM had a medi-
an duration of imatinib therapy of 73 months without
having reached MR4.5 despite a median daily dose of
500mg/d; second, our own estimate of the spontaneous
rate of MMR toMR4.5 progressions in a parallel cohort of
CML patients with characteristics closely similar to those
of ACTIM was 23%. In agreement with the expected bio-
logical effects of pioglitazone,15 a significant decline in
STAT5 transcription and CFC numbers was evidenced in
normal bone marrow from CML patients of the ACTIM
trial. Interestingly, decreasing CFC levels were positively
correlated with favorable kinetics of MR4.5 conversions.
Because pioglitazone is well tolerated in most dia-
betic patients and is not hypoglycemogenic in normal
individuals, the only substantial safety concern regarding
the use of pioglitazone was the slight increased risk of
bladder cancer reported in type 2 diabetes patients with
long-term exposure to the drug. However, the increased
risk was deemed sufficiently small by the US Food and
Drug Administration and other foreign bodies to not sus-
pend the drug’s market authorization in light of its
expected benefit for the treatment of diabetes.16,17 Even
in France, where the drug has been withdrawn by the reg-
ulatory authority, a special authorization was granted to
pursue the first step of the ACTIM trial to completion.
Importantly, 2 recent epidemiologic studies are now
questioning this previous alert by concluding that piogli-
tazone exposure was not associated with an increased risk
of bladder cancer.20,21 No bladder tumor was detected
during follow-up in the ACTIM study.
Other approaches are currently tested in an effort to
eliminate CML stem cells. The Hedgehog pathway was
targeted by means of smoothened (SMO) inhibitors. Two
inhibitors were tested in the clinic, LDE225 and BMS-
833923. Their safety profile was not favorable, and no evi-
dence of efficacy was reported.22,23 Preclinical data on
Figure 3. Associated biomarkers STAT5 and CFC in bone
marrow CD341cells.Boxes represent the 5th to 95th percen-
tiles; horizontal bars represent the median; vertical brackets
represent the ranges. (A) STAT5 messenger RNA expression
relative to GAPDH messenger RNA. Number of patients test-
ed: 18 before pioglitazone initiation, 20 at 6 months, and 5 at
12 months. (B) CFC numbers. Number of patients tested: 20
before pioglitazone initiation, 19 at 6 months, and 5 at 12
months.
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animal models suggest that inhibiting the Wnt/beta-cate-
nin pathway may also be of interest.24 Ongoing studies
have highlighted targets that are “drugable” with reposi-
tioned commercially available compounds such as inter-
feron, arsenic trioxide, or JAK2 inhibitors. The
combination of pegylated interferon 2a or 2b to imatinib
in patients with newly diagnosed chronic phase CML
resulted in higher rates and deeper molecular responses in
2 prospective randomized trial.25,26 Combined interferon
and arsenic treatment was shown to prolong the survival
of primary CML mice and to impair severely CML en-
graftment into untreated secondary recipients, thereby
showing a major decrease in CML leukemia initiating cell
activity.27,28 Another approach that targets JAK2 with
ruxolitinib together with nilotinib has been reported to
enhance the elimination of primary human CML stem
cells in vitro, and ongoing clinical investigations are
attempting to achieve disease eradication.29
In conclusion, the results of the ACTIM study
reported here suggest that pioglitazone together with ima-
tinib increases the proportion of CML patients who
achieve MR4.5, further suggesting that the ability of
PPAR-c agonists to erode the CML stem cell pool may be
of clinical benefit for CML patients.15 The combination
was well tolerated and may be continued as long as the
BCR-ABL1 signal remains detectable. The corroborating
ACTIW randomized trial is currently recruiting to ad-
dress the questions that remain, such as the optimal dura-
tion of the combination and the ideal PPAR-c agonist to
be used. Discontinuation of both PPAR-c agonist and
TKI while obtaining a high rate of sustained treatment-
free remission is currently being tested and would be the
ultimate proof of the possibility of CML eradication and
cure using this approach.
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